
John S. Kenyon
Examiner (ID: 14775, Phone: (571)270-1567 , Office: P/1625 )
| Most Active Art Unit | 1625 |
| Art Unit(s) | 1625, 1622 |
| Total Applications | 1198 |
| Issued Applications | 827 |
| Pending Applications | 159 |
| Abandoned Applications | 267 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20100216
[patent_doc_number] => 20250230152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 19/097371
[patent_app_country] => US
[patent_app_date] => 2025-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26449
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19097371
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/097371 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | Mar 31, 2025 | Pending |
Array
(
[id] => 19862249
[patent_doc_number] => 20250101035
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => CRYSTALLINE FORMS OF A MENIN INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/827512
[patent_app_country] => US
[patent_app_date] => 2024-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9517
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18827512
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/827512 | Crystalline forms of a menin inhibitor | Sep 5, 2024 | Issued |
Array
(
[id] => 19940251
[patent_doc_number] => 12312373
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Cyclopropane skeleton monophosphine ligands, palladium complexes thereof, preparation methods and application
[patent_app_type] => utility
[patent_app_number] => 18/783334
[patent_app_country] => US
[patent_app_date] => 2024-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 4505
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18783334
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/783334 | Cyclopropane skeleton monophosphine ligands, palladium complexes thereof, preparation methods and application | Jul 23, 2024 | Issued |
Array
(
[id] => 20328363
[patent_doc_number] => 12458620
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Process for production of essentially pure D
[patent_app_type] => utility
[patent_app_number] => 18/765229
[patent_app_country] => US
[patent_app_date] => 2024-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 13587
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18765229
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/765229 | Process for production of essentially pure D | Jul 5, 2024 | Issued |
Array
(
[id] => 20452987
[patent_doc_number] => 12516037
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Substituted thiophenecarboxamides and analogues as antibacterials agents
[patent_app_type] => utility
[patent_app_number] => 18/591732
[patent_app_country] => US
[patent_app_date] => 2024-02-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24103
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18591732
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/591732 | Substituted thiophenecarboxamides and analogues as antibacterials agents | Feb 28, 2024 | Issued |
Array
(
[id] => 19389338
[patent_doc_number] => 20240279208
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
[patent_app_type] => utility
[patent_app_number] => 18/588874
[patent_app_country] => US
[patent_app_date] => 2024-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588874
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/588874 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | Feb 26, 2024 | Pending |
Array
(
[id] => 19599450
[patent_doc_number] => 20240390330
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES
[patent_app_type] => utility
[patent_app_number] => 18/434505
[patent_app_country] => US
[patent_app_date] => 2024-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37657
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434505
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/434505 | ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES | Feb 5, 2024 | Pending |
Array
(
[id] => 19210659
[patent_doc_number] => 11999707
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-06-04
[patent_title] => N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/427924
[patent_app_country] => US
[patent_app_date] => 2024-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3965
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427924
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/427924 | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound | Jan 30, 2024 | Issued |
Array
(
[id] => 20451806
[patent_doc_number] => 12514849
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
[patent_app_type] => utility
[patent_app_number] => 18/427477
[patent_app_country] => US
[patent_app_date] => 2024-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 7957
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427477
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/427477 | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | Jan 29, 2024 | Issued |
Array
(
[id] => 19112726
[patent_doc_number] => 20240124476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/396432
[patent_app_country] => US
[patent_app_date] => 2023-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14167
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396432
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/396432 | MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME | Dec 25, 2023 | Pending |
Array
(
[id] => 19151155
[patent_doc_number] => 11976051
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-05-07
[patent_title] => N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/395377
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4056
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395377
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/395377 | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | Dec 21, 2023 | Issued |
Array
(
[id] => 19233667
[patent_doc_number] => 20240190859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/536859
[patent_app_country] => US
[patent_app_date] => 2023-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24841
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -58
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18536859
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/536859 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | Dec 11, 2023 | Pending |
Array
(
[id] => 19359229
[patent_doc_number] => 20240261263
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/530467
[patent_app_country] => US
[patent_app_date] => 2023-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11027
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18530467
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/530467 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS | Dec 5, 2023 | Pending |
Array
(
[id] => 19048564
[patent_doc_number] => 20240090533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONS
[patent_app_type] => utility
[patent_app_number] => 18/515987
[patent_app_country] => US
[patent_app_date] => 2023-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2734
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515987
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/515987 | METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONS | Nov 20, 2023 | Pending |
Array
(
[id] => 19186190
[patent_doc_number] => 20240165103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/389356
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18389356
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/389356 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | Nov 13, 2023 | Pending |
Array
(
[id] => 19125814
[patent_doc_number] => 20240131167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => EGFR Degraders and Associated Methods of Use
[patent_app_type] => utility
[patent_app_number] => 18/497586
[patent_app_country] => US
[patent_app_date] => 2023-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17402
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 1974
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497586
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/497586 | EGFR Degraders and Associated Methods of Use | Oct 29, 2023 | Pending |
Array
(
[id] => 19345141
[patent_doc_number] => 20240254104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => SOLID FORMS OF AN HIV CAPSID INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/383128
[patent_app_country] => US
[patent_app_date] => 2023-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30938
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18383128
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/383128 | Solid forms of an HIV capsid inhibitor | Oct 23, 2023 | Issued |
Array
(
[id] => 19331239
[patent_doc_number] => 20240245669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => Choline Salt Forms of an HIV Capsid Inhibitor
[patent_app_type] => utility
[patent_app_number] => 18/383144
[patent_app_country] => US
[patent_app_date] => 2023-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18383144
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/383144 | Choline Salt Forms of an HIV Capsid Inhibitor | Oct 23, 2023 | Pending |
Array
(
[id] => 19504964
[patent_doc_number] => 12116375
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Compositions and methods for treating cancer
[patent_app_type] => utility
[patent_app_number] => 18/490700
[patent_app_country] => US
[patent_app_date] => 2023-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 58
[patent_no_of_words] => 61094
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 391
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18490700
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/490700 | Compositions and methods for treating cancer | Oct 18, 2023 | Issued |
Array
(
[id] => 19360754
[patent_doc_number] => 20240262788
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => UREA AND MELAMINE PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 18/293947
[patent_app_country] => US
[patent_app_date] => 2023-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11012
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 202
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18293947
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/293947 | Urea and melamine production | Oct 12, 2023 | Issued |